Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus SANCTURA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus SANCTURA.
DICYCLOMINE HYDROCHLORIDE vs SANCTURA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Trospium chloride is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, thereby reducing detrusor muscle contractions and increasing bladder capacity.
10-20 mg orally 3-4 times daily
20 mg orally twice daily, with or without food. Maximum dose 20 mg twice daily.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life is approximately 12–20 hours in healthy adults, allowing twice-daily dosing.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for ~30%.
Category A/B
Category C
Anticholinergic
Anticholinergic